Australia's Incannex Healthcare gains on partnering with U.S. firm
03/03/2023 01:45
** Shares of Incannex Healthcare Ltd IHL.AX rise as much
as 11.5% to A$0.145, on track for best day since Feb. 6, if
gains hold
** Cannabinoid pharmaceutical engages with U.S.-based
Catalent Inc CTLT.N to develop psilocybin drug product
** Says product to be used for IHL's proprietary
psilocybin-assisted psychotherapy drug development program and
commercial use
** Stock down ~28% this year, since last close
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com;))
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed